Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2015

01-12-2015

The Use of Biologic Therapies in Uveitis

Authors: Sergio Schwartzman, Monica Schwartzman

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2015

Login to get access

Abstract

Therapy for autoimmune ophthalmic disease is currently evolving. The improved understanding of the abnormal immune response in the various forms of uveitis has resulted in targeted therapy. The aberrations of the immune system have been characterized by atypical cell populations, cytokine expression, and cell–cell interactions. Different patterns of cytokine expression have now been delineated in the abnormal uveal tract with exaggerated and/or abnormal expression of TNF, IL-1, IL-2, IL-6, and IL-17. The development of therapies for other conditions in which these cytokines play an important role has resulted in the availability of biological agents that have been adopted for use in the therapy for uveitis. Adalimumab and infliximab have been the best studied anti-TNF agents and indeed have now been recommended by an expert panel as first-line treatment of ocular manifestations of Behçet’s disease and second-line treatment for other forms of uveitis (Levy-Clarke et al. (Ophthalmology, 2013). Other anti-TNF agents have been studied as well. Daclizumab, a monoclonal antibody directed against the IL-2 receptor, has also demonstrated utility in treating uveitis as have some of the anti-IL1 agents. Gevokizumab has been granted orphan drug designation for the treatment of resistant forms of uveitis. Therapies affecting IL-6, including tocilizumab are being studied, and available medications that block antigen presenting cell and T cell interaction such as abatacept have been reported to be effective in uveitis. Interferons as well as rituximab have also been evaluated in small studies. Although these biologic therapies have provided a larger armamentarium to treat uveitis, challenges remain. Uveitis is not a single illness; rather, it is a manifestation of many potential systemic diseases that may have very specific individual therapeutic targets. Identifying and characterizing these underlying diseases is not always achieved, and more importantly, the most effective therapies for each entity have not been defined.
Literature
1.
Levy-Clarke, G., et al., Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology, 2013.
2.
Ali A, Rosenbaum JT (2010) Use of methotrexate in patients with uveitis. Clin Exp Rheumatol 28(5 Suppl 61):S145–S150PubMed
3.
Kaplan-Messas A et al (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11(2):131–139CrossRefPubMed
4.
Deuter CM et al (2009) Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 17(6):415–419CrossRefPubMed
5.
Klisovic DD (2012) Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol 51:57–62CrossRefPubMed
6.
Dick AD, Azim M, Forrester JV (1997) Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 81(12):1107–1112PubMedCentralCrossRefPubMed
7.
Figueroa MS, Ciancas E, Orte L (2007) Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol 17(1):69–74PubMed
8.
Hogan AC et al (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5):1000–1006CrossRefPubMed
9.
Vitale AT, Rodriguez A, Foster CS (1996) Low-dose cyclosporin a therapy in treating chronic, noninfectious uveitis. Ophthalmology 103(3):365–373, discussion 373–4CrossRefPubMed
10.
Kahn P et al (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113(5):860–864, e2CrossRefPubMed
11.
Mangge H et al (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 23(5):258–261CrossRefPubMed
12.
Rajaraman RT et al (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113(2):308–314CrossRefPubMed
13.
Richards JC et al (2005) Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33(5):461–468CrossRef
14.
Sharma SM et al (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 66(6):840–841PubMedCentralCrossRefPubMed
15.
Simonini G et al (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 63(4):612–618CrossRef
16.
Tynjala P et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548–550PubMedCentralCrossRefPubMed
17.
Zannin ME et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 40(1):74–79CrossRefPubMed
18.
Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451CrossRefPubMed
19.
Matsuda J et al (2013) Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol 57(1):104–107CrossRefPubMed
20.
Papadia M, Herbort CP (2010) Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm 18(6):482–484CrossRefPubMed
21.
Ally MR, Veerappan GR, Koff JM (2008) Treatment of recurrent Crohn’s uveitis with infliximab. Am J Gastroenterol 103(8):2150–2151CrossRefPubMed
22.
Fries W et al (2002) Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol 97(2):499–500CrossRefPubMed
23.
Benitez-del-Castillo JM et al (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 19(8):841–845CrossRef
24.
Suhler EB et al (2009) Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 127(6):819–822PubMed
25.
Suhler EB et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903–912CrossRefPubMed
26.
Kruh JN et al (2014) Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 121(1):358–364CrossRefPubMed
27.
Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149(4):572–575CrossRefPubMed
28.
Tynjala P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339–344CrossRef
29.
Turel Ermertcan, A., et al., Psoriatic uveitis responding to adalimumab therapy. Int J Dermatol, 2013.
30.
Takase K et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 31(2):243–245CrossRefPubMed
31.
Suhler EB et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97(4):481–486CrossRefPubMed
32.
Soheilian M et al (2012) Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab. J Cataract Refract Surg 38(6):1094–1096CrossRefPubMed
33.
Simonini G et al (2013) Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 11(1):16PubMedCentralCrossRefPubMed
34.
Seve P et al (2012) Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 20(1):59–60CrossRefPubMed
35.
Sen ES et al (2012) Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease—a case cohort interventional study. Rheumatology (Oxford) 51(12):2199–2203CrossRef
36.
Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701PubMedCentralCrossRefPubMed
37.
Ramanan AV et al (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14PubMedCentralCrossRefPubMed
38.
Mushtaq B et al (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond) 21(6):824–825CrossRef
39.
40.
41.
Magli A et al (2013) Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251(6):1601–1606CrossRefPubMed
42.
Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475–481CrossRefPubMed
43.
Leccese P et al (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S93PubMed
44.
Kotaniemi K, Saila H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429PubMedCentralCrossRefPubMed
45.
Garcia-De-Vicuna C et al (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm 2013:560632CrossRef
46.
Erckens RJ et al (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 250(5):713–720PubMedCentralCrossRefPubMed
47.
Dobner BC et al (2013) A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 97(2):134–138CrossRefPubMed
48.
Diaz-Llopis M et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575–1581CrossRefPubMed
49.
Diaz-Llopis M et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361CrossRefPubMed
50.
Cordero-Coma M et al (2013) Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm 21(3):212–219CrossRefPubMed
51.
Callejas-Rubio JL et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(6):613–614, author reply 614CrossRefPubMed
52.
Calleja S et al (2012) Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(−) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond) 26(3):468–477CrossRef
53.
Bravo-Ljubetic L et al (2013) Adalimumab therapy for refractory childhood uveitis. J AAPOS 17(5):456–459CrossRefPubMed
54.
55.
Androudi S et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117(8):1612–1616CrossRefPubMed
56.
William M et al (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2(4):231–233PubMedCentralCrossRefPubMed
57.
Miserocchi, E., et al., Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm, 2013.
58.
Miserocchi E et al (2013) Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 31(2):320–321PubMed
59.
Mesquida M et al (2013) Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21(2):160–162CrossRefPubMed
60.
Faez, S., et al., Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol, 2013.
61.
62.
Reiff A et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44(6):1411–1415CrossRefPubMed
63.
Smith BJ, McMillan VM, Newton JS (2001) Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J Clin Rheumatol 7(3):175–178CrossRefPubMed
64.
Foster CS et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437–440CrossRefPubMed
65.
Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008–1011CrossRef
66.
Smith JA et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18–23CrossRefPubMed
67.
Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56(10):3248–3252CrossRefPubMed
68.
Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229CrossRefPubMed
69.
Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959CrossRefPubMed
70.
Balshem H et al (2011) GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 64(4):401–406CrossRefPubMed
71.
Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27(1):1–18CrossRefPubMed
72.
Nussenblatt RB et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96(13):7462–7466PubMedCentralCrossRefPubMed
73.
Nussenblatt RB et al (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21(3):283–293CrossRefPubMed
74.
Yeh S et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31(2):91–97PubMedCentralCrossRefPubMed
75.
Nussenblatt RB et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770CrossRefPubMed
76.
Wroblewski K et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46(4):322–328PubMedCentralCrossRefPubMed
77.
Chi W et al (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119(5):1218–1224CrossRefPubMed
78.
Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787CrossRefPubMed
79.
80.
Emmi G et al (2013) Anakinra for resistant Behcet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMed
81.
Teoh SC et al (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263–264PubMedCentralCrossRefPubMed
82.
Gul A et al (2012) Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566CrossRefPubMed
83.
Petrinovic-Doresic J et al (1999) Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm 7(2):75–84CrossRefPubMed
84.
Muselier A et al (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382–383CrossRefPubMed
85.
Tappeiner C et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295CrossRefPubMed
86.
Adan A et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251(11):2627–2632CrossRefPubMed
87.
Tsang, A.C., J. Roth, and C. Gottlieb, Tocilizumab for Severe Chronic Anterior Uveitis Associated with Juvenile Idiopathic Arthritis in a Pediatric Patient. Ocul Immunol Inflamm, 2013.
88.
Plskova J, Greiner K, Forrester JV (2007) Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55–61CrossRefPubMed
89.
Kenawy N et al (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249(2):297–300CrossRefPubMed
90.
91.
92.
Zulian F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62(6):821–825CrossRef
93.
Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis—a case report. J Rheumatol 35(9):1897–1898PubMed
94.
Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article By Zulian et al. Arthritis Care Res 63(2):307–308, author reply 308CrossRef
95.
Parikh JG, Tawansy KA, Rao NA (2008) Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115(10):1833–1836CrossRefPubMed
96.
Heiligenhaus A et al (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50(8):1390–1394CrossRef
97.
Tappeiner C et al (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39(3):184–186CrossRefPubMed
98.
Yuksel E et al (2014) Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis. J Ocul Pharmacol Ther 30(1):74–80CrossRefPubMed
99.
Markomichelakis N et al (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541, e1CrossRefPubMed
100.
Hosseini H et al (2009) Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 19(5):818–823PubMed
101.
Farvardin M, Afarid M, Shahrzad S (2012) Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 28(6):628–631PubMed
102.
Farvardin M et al (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30(9):1530–1535CrossRefPubMed
Metadata
Title
The Use of Biologic Therapies in Uveitis
Authors
Sergio Schwartzman
Monica Schwartzman
Publication date
01-12-2015
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2015
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-014-8455-6

Other articles of this Issue 3/2015

Clinical Reviews in Allergy & Immunology 3/2015 Go to the issue

ReviewPaper

Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment

ReviewPaper

A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye

ReviewPaper

Ocular Involvement in Systemic Autoimmune Diseases

OriginalPaper

IL-35 and Autoimmunity: a Comprehensive Perspective

OriginalPaper

T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review

ReviewPaper

Current Approach to Dry Eye Disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits